WilmerHale Counsels Vividion in Strategic Research Collaboration with Celgene

  • 3.20.2018

Vividion Therapeutics, a biotechnology company using novel proteomics and chemistry platforms, has announced that it entered into a strategic research collaboration with Celgene Corporation and will receive $101 million in upfront and equity consideration. The multi-year collaboration will focus on the identification and development of small molecules that function through the ubiquitin proteasome system, modulating specific protein levels for therapeutic benefit, against targets for a range of oncology, neurodegenerative and inflammatory indications.

The WilmerHale deal team counseling Vividion included Steven Singer, Steven Barrett and Mat Trachok.

Read Vividion Therapeutics' press release for more information.

See related industries:

Life Sciences